Jericho Sciences is developing novel antiviral therapeutics and corresponding personalized diagnostic assays which specifically address the limitations of current combination antiretroviral therapy (cART) in the clinical management of HIV-1 infection. The target viral motif of our lead small molecule is shared across multiple virus families.
